Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Marinus applies Ligand's Captisol to its ganaxolone

Executive Summary

Ligand Pharmaceuticals Inc. granted Marinus Pharmaceuticals Inc. exclusive worldwide rights to use its Captisol drug delivery technology (which Ligand will exclusively supply) to formulate Marinus' intravenous ganaxolone, a synthetic analog of the naturally occurring neuroactive steroid allopregnanolone, and a positive allosteric modulator of the GABA-A receptor, which exhibits both anticonvulsive and antianxiety effects.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register